

Gabriele BÃ¼chel

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/990963/publications.pdf>

Version: 2024-02-01

9
papers

370
citations

1163117

8
h-index

1474206

9
g-index

10
all docs

10
docs citations

10
times ranked

694
citing authors

#	ARTICLE	IF	CITATIONS
1	Recruitment of BRCA1 limits MYCN-driven accumulation of stalled RNA polymerase. <i>Nature</i> , 2019, 567, 545-549.	27.8	76
2	Association with Aurora-A Controls N-MYC-Dependent Promoter Escape and Pause Release of RNA Polymerase II during the Cell Cycle. <i>Cell Reports</i> , 2017, 21, 3483-3497.	6.4	71
3	Potential of novel antiretrovirals to modulate expression and function of drug transporters in vitro. <i>Journal of Antimicrobial Chemotherapy</i> , 2011, 66, 802-812.	3.0	60
4	Combined inhibition of Aurora-A and ATR kinases results in regression of MYCN-amplified neuroblastoma. <i>Nature Cancer</i> , 2021, 2, 312-326.	13.2	50
5	MiR-205-driven downregulation of cholesterol biosynthesis through SQLE-inhibition identifies therapeutic vulnerability in aggressive prostate cancer. <i>Nature Communications</i> , 2021, 12, 5066.	12.8	34
6	Next-generation RNA sequencing reveals differential expression of MYCN target genes and suggests the mTOR pathway as a promising therapy target in MYCN-amplified neuroblastoma. <i>International Journal of Cancer</i> , 2013, 132, E106-15.	5.1	26
7	Drugging the "Undruggable" MYCN Oncogenic Transcription Factor: Overcoming Previous Obstacles to Impact Childhood Cancers. <i>Cancer Research</i> , 2021, 81, 1627-1632.	0.9	25
8	Immune response modulation by Galectin-1 in a transgenic model of neuroblastoma. <i>Oncolmmunology</i> , 2016, 5, e1131378.	4.6	18
9	TrkB-Target Galectin-1 Impairs Immune Activation and Radiation Responses in Neuroblastoma: Implications for Tumour Therapy. <i>International Journal of Molecular Sciences</i> , 2018, 19, 718.	4.1	6